



Rosalie Liccardo Pacula is a Senior Economist at the RAND Corporation and a Professor at the Pardee RAND Graduate School. She serves as Director of RAND's BING Center for Health Economics and is co-director of the RAND's Drug Policy Research Center. Her research at RAND over the last 20 years has largely focused on issues related to illegal or imperfect markets (health care markets, insurance markets, and illicit drug markets): measurement of the size of these markets, the impact they have on behaviour, and the effectiveness of policy interventions at targeting behaviour within these markets. She was the lead investigator of several NIH studies examining the impact of marijuana liberalization policies (decriminalization, medicalization and legalization) on use and public health as well as their impact on the use of other substances (alcohol,

prescription opioids and heroin). She has also been actively engaged in evaluating the impact of recent policies to expand treatment, particularly for opioid use, in the United States. With RAND colleagues she has explored the role of state policies in influencing the diffusion of evidence based treatment for opioid abuse within the Medicaid population, examined broader market and state policies that have been important for influencing the opioid epidemic (including Prescription Drug Monitoring Programs, general Good Samaritan laws, pill mill laws, triple prescription laws, and parity insurance laws), and she has developed a modelling tool to measure trends in prescription drug misuse among active service members. Her work on prescription drugs specifically has covered misuse in a variety of communities and populations, including the elderly, the disabled, and the poor.

Dr. Pacula is a member of the National Bureau of Economic Research (NBER) and a regular scientific reviewer for the National Institutes of Health, National Science Foundation, and a number of foundations and journals. She has been part of the research teams providing guidance to Washington state, Vermont and Canada on their legalization initiatives, focusing on public health aspects of these laws. Currently she serves as an advisor to the Robert Wood Johnson Foundation's Public Health Law Research Program, the NIDA- funded Monitoring the Future Survey project, and the NIAAA APIS system. She is the Vice President of the *International Society for the Study of Drug Policy (ISSDP)*, and was recently selected as one of 7 members of the NIDA Advisory Council Workgroup on Marijuana Policy. She sits on the editorial boards of the *International Journal of Drug Policy* and the *Journal of Drug Policy Analysis*. She is also an Assistant Editor for *Addiction*.